Meet Our New Board Members: Scott Biller

Published

June 16, 2022

Meet Our New Board Members: Scott Biller

In this new series, we are introducing the new additions to the OMass Board of Directors following our latest round of financing. The aim is to learn a bit more about our new board members and why they were excited to join OMass’s journey.

Scott Biller is currently an Executive Venture Partner at GV. He was previously the CSO of Agios, where he led the efforts to discover three approved medicines (TIBSOVO®, IDHIFA® and PYRUKYND®). Prior to that, Scott held various R&D leadership roles at Novartis and BMS.

 

What attracted you to OMass initially?

I found the platform technology based on native-MS to be highly enabling and scientifically compelling. The ability to study protein targets in a test tube in a way that closely mimics the way they look and behave in living cells is extremely powerful and has the potential to lead to novel drugs with new mechanisms of action.

What makes OMass unique?

The most unique and compelling aspect of OMass is the superb scientific team that has been assembled. The technology platform and program portfolio are very promising, but it is the superb team that will drive future success.

What excites you most about the company over the next couple of years?

The aspect that excites me most is bringing therapeutic concepts to realization and clinical testing in patients, with the goal of relieving human disease and suffering. OMass has the potential to move several clinical candidates into human evaluation over the next few years and that is extremely exciting.

Tell us a fun fact about yourself.

I grew up in New York City a short walk from a beautiful beach on the Atlantic Ocean. Many people do not realize that New York City is more than Manhattan skyscrapers, and that there is a wonderful mix of urbanity and nature (picture below).

MORERelated News
On Rare Diseases: In Conversation with Dr Birgitte Volck, Non-Executive Board Director, OMass Therapeutics
Our new non-executive board member Birgitte Volck MD, PhD has decades of experience at companies developing new therapies to treat...
Remembering Prof. Graham Richards, Founding Chair of OMass Therapeutics
It is with heavy hearts that we remember our dear friend Prof. Graham Richards, a colleague, mentor and the first...
Looking Back on 2024: A Year of Progress at OMass Therapeutics
As 2024 draws to a close, it’s great to reflect on the progress we’ve made at OMass. It’s been a...